IL6 and rheumatoid arthritis: IL‐6 inhibitors such as tocilizumab are currently licenced for use in rheumatoid arthritis, juvenile arthritis and more recently have been under investigation for treatment of excessive inflammation in patients with severe acute respiratory syndrome coronavirus 2 infection.18